Genomic Health, Inc. (GHDX): Earnings News

GHDX – Misses Wall Street consensus EPS estimates by $0.02 and misses on revenues.


Key Facts Surrounding This News Item


  • GHDX had a POWR Rating of C (Neutral) coming into today.
  • GHDX was 3.48% above its 10-Day Moving Average coming into today.
  • GHDX was 2.05% above its 20-Day Moving Average coming into today.
  • GHDX was -1.48% below its 50-Day Moving Average coming into today.
  • GHDX was 1.93% above its 100-Day Moving Average coming into today.
  • GHDX was 3.40% above its 200-Day Moving Average coming into today.
  • GHDX had returned -2.78% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Genomic Health, Inc. (GHDX)


Genomic Health provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company was founded in 2000 and is based in Redwood City, California. View our full GHDX ticker page with ratings, news, and more.

GHDX at a Glance

GHDX Current POWR Rating™
Overall POWR Rating™
GHDX Current Price $73.50 0.82%
More GHDX Ratings, Data, and News

GHDX Price Reaction

The day of this event (Mar. 8, 2018)
GHDX Closing Price$31.51 5.23%
GHDX Volume358,300
157.66% from avg
Leading up to this event
GHDX 1-mo return0.33%
After this event
GHDX 1-day return0.42%
GHDX 3-day return2.56%
GHDX 5-day return2.78%

GHDX Price Chart


The Top Stocks For 2019

More Genomic Health, Inc. (GHDX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GHDX News
Page generated in 0.8776 seconds.